Suchergebnisse - "Calogero Vetro"

PubPharm (30)

1

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

in: Frontiers in Oncology | 2023

von Giuseppe A. Palumbo | Daniela Cambria | Enrico La Spina | +9

2

Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data

in: Healthcare | 2023

von Lucia Gozzo | Antonella Nardo | Serena Brancati | +14

3

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience

in: Frontiers in Immunology | 2023

von Andrea Duminuco | Andrea Duminuco | Uros Markovic | +14

4

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.

in: HemaSphere | 2023

von Federica Lessi | Erika Borlenghi | Chiara Sartor | +8

5

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS

in: HemaSphere | 2023

von Andrea Duminuco | Antonella Nardo | Alessandra Orofino | +17

6

P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY

in: HemaSphere | 2023

von Domenico Russo | Nicola Polverelli | Marika Vezzoli | +27

7

in: Hematology Reports | 2022

von Andrea Duminuco | Calogero Vetro | Cinzia Maugeri | +7

8

Target Therapy for Extramedullary Relapse of

in: Cancers | 2022

von Andrea Duminuco | Cinzia Maugeri | Marina Parisi | +9

9

Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes

in: Journal of Clinical Medicine | 2022

von Calogero Vetro | Valeria Di Giacomo | Donato Mannina | +9

10

Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting

in: Journal of Clinical Medicine | 2022

von Andrea Duminuco | Antonella Nardo | Bruno Garibaldi | +5